ArticlePLOS digital health2026
Rapid antithrombin assay from human blood plasma utilizing smartphone-based flow observation on paper chips.
Article in PLOS digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antithrombin (AT) is a protein that plays a critical role in regulating the coagulation cascade. Currently available methods for detecting AT levels are not portable, rapid, or simple enough to be used in urgent and clinical settings. This work presents a novel method for detecting AT levels from human blood through the smartphone-based capillary flow observation on paper chips. Assays were initially conducted with AT-spiked phosphate-buffered saline (PBS), demonstrating high linearity (R² = 0.988) between flow velocity and the logarithm of AT concentration (ng/mL), with a linear range of up to 12 ng/mL. Assays were also conducted on diluted human plasma samples, showing increasing, plateaued, and decreasing regions over the AT concentrations, respectively. A high linearity (R2 = 0.973) was observed within the linear range up to 19 ng/mL. This behavior mirrors the classic Heidelberger-Kendall antibody-antigen precipitation assay, characterized by a bell-shaped curve, despite substantial differences in assay mechanisms and a concentration range that is orders of magnitude lower. To validate this similarity, we directly measured the extent of particle immunoagglutination on the paper chips using a smartphone-based fluorescence microscope and confirmed the same bell-shaped curve. These results indicate that capillary flow velocity is positively correlated with the extent of particle immunoagglutination. Using multiple human blood samples (n = 14; each subject was tested three times), the smartphone-based flow velocity AT assay was compared with ELISA, and a strong correlation was observed. The assay was essentially near-real-time, as only the first 35 frames (1.17 seconds) of data were required, provided that the antibody-conjugated particles were pre-loaded on the paper chip before the assay. It requires only a paper chip and a smartphone, and involves only one pipetting step for sample loading. This assay could one day address the critical need for determining AT deficiency and support clinicians in managing patients' anticoagulation status.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.